Brief: Kedrion Biopharma Announces The Extension Of A U.S. Agreement With Grifols To Support Long-Term And Continued Access To Gammaked®
18/08/2026 13:02
BRIEF-Kedrion Biopharma Announces The Extension Of A U.S. Agreement With Grifols To Support Long-Term And Continued Access To Gammaked® Grifols, S.A. GRLS.MC:
KEDRION BIOPHARMA ANNOUNCES THE EXTENSION OF A U.S. AGREEMENT WITH GRIFOLS TO SUPPORT LONG-TERM AND CONTINUED ACCESS TO GAMMAKED®
KEDRION BIOPHARMA: DEAL MAINTAINS KEY THERAPIES WITHIN KEDRION'S U.S. IMMUNODEFICIENCY AND AUTO IMMUNE DISORDERS PORTFOLIO
Source text: ID:nPn32hylKa
Further company coverage: GRLS.MC
Recent news on Grifols
See all newsSpanish stocks - Factors to watch on Nov 3
Brief: Grifols Approves Interim Dividend Of €0.15/Shr Payable On Dec 4
Brief: Grifols Q3 Group Profit €162 Mln
Refile: Grifols says Canada plasma license suspension has no impact on ongoing operations
Brief: Health Canada Suspends Licence Of Grifols Site In Winnipeg - Globe And Mail